- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07950007
ctDNA-Guided Neoadjuvant Therapy in HER2+ Breast Cancer
Individualized Neoadjuvant De-Escalation of T-DXd in HER2+ Breast Cancer (INDEX-HER2)
The convergence of evidence from neoCARHP (comparable pCR between TCHP and THP in an unselected population), DB-11 (activity of T-DXd-THP in high-risk HER2-positive early breast cancer), and I-SPY2 ctDNA data (early ctDNA clearance predicts favorable response and outcomes) provides a strong rationale for biomarker-guided treatment selection. This study uses early on-treatment ctDNA response after standardized THP induction to direct therapy intensity rather than reflexively escalating all patients.
Unlike non-biomarker-selected escalation approaches, this study uses ctDNA as a dynamic biomarker to tailor therapy: patients with early molecular clearance continue THP without carboplatin or ADC exposure, while patients with persistent molecular tumor burden escalate to T-DXd.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Clinical Trials Navigator
- Telefonnummer: 310-423-2133
- E-post: groupcancertrialinformation@cshs.org
Studieorter
-
-
California
-
Beverly Hills, California, Förenta staterna, 90212
- Cedars-Sinai Medical Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
Newly diagnosed, histologically confirmed stage II-III HER2-positive breast cancer (HER2-positive defined per ASCO/CAP guidelines: IHC 3+ or ISH-amplified)
-
No prior systemic therapy for breast cancer
-
Adequate tumor tissue available for molecular profiling and ctDNA assay design
-
Adequate peripheral blood samples obtainable for serial ctDNA testing
-
Age ≥ 18 years
-
ECOG performance status 0-2
-
Adequate organ function as defined by:
- Absolute neutrophil count (ANC) ≥ 1,500/µL
- Platelets ≥ 100,000/µL
- Hemoglobin ≥ 9.0 g/dL
- Total bilirubin ≤ 1.5 × upper limit of normal (ULN)
- AST/ALT ≤ 2.5 × ULN
- Creatinine clearance ≥ 50 mL/min (Cockcroft-Gault)
- Left ventricular ejection fraction (LVEF) ≥ 55% by echocardiogram or MUGA scan
-
Women of childbearing potential must have a negative pregnancy test and agree to use effective contraception during treatment and for the protocol-specified period after the last dose of HER2-directed therapy/T-DXd, per applicable prescribing information and institutional standards.
-
Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.
Exclusion Criteria:
- Distant metastatic disease (Stage IV)
- Prior invasive breast cancer within the past 5 years
- Prior chemotherapy, radiation therapy, or targeted therapy for current breast cancer
- Known hypersensitivity to any component of the treatment regimen, including docetaxel, trastuzumab, pertuzumab, or T-DXd
- Active cardiac disease including: congestive heart failure (NYHA Class II or above), unstable angina, myocardial infarction within 6 months, uncontrolled hypertension, or clinically significant arrhythmia
- Pregnant or breastfeeding
- History of, or current, interstitial lung disease/pneumonitis; active uncontrolled infection requiring systemic therapy
- Any other condition that, in the opinion of the investigator, would make the patient unsuitable for study participation.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Enkelarm
|
All patients begin with THP for Cycles 1-4. ctDNA is assessed at baseline,C2D1, C5D1, and at the preoperative and postoperative time points. C2D1 ctDNA determines subsequent treatment: ctDNA-negative patients continue THP through C6, while ctDNA-positive patients escalate to T-DXd from C5 through C8 after 4 cycles of THP. A tumor-informed, personalized ctDNA assay will be used. Whole genome sequencing (WGS) will be performed on formalin-fixed paraffin-embedded (FFPE) tumor tissue and matched-normal DNA from buffy coat to identify somatic variants. Based on the WGS results, multiplex PCR primers will be designed for 64 tumor-specific, somatic single-nucleotide variants for each patient. A sample will be considered ctDNA-positive if ≥2 of 64 variants are detected in the circulating cell-free DNA. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
pCR rate in the HR-positive/HER2-positive group
Tidsram: Time of Surgery, up to 24 weeks post on study
|
Pathologic complete response (pCR) is defined as the absence of residual invasive cancer in the breast and regional lymph nodes (ypT0/is ypN0) at the time of surgery following completion of neoadjuvant therapy. |
Time of Surgery, up to 24 weeks post on study
|
|
pCR rate in the HR-negative/HER2-positive group
Tidsram: Time of Surgery, up to 24 weeks post on study
|
Pathologic complete response (pCR) is defined as the absence of residual invasive cancer in the breast and regional lymph nodes (ypT0/is ypN0) at the time of surgery following completion of neoadjuvant therapy. |
Time of Surgery, up to 24 weeks post on study
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
ctDNA Clearance Rate
Tidsram: From enrollment to end of treatment at 8 cycles (24 weeks)
|
Patients who achieve ctDNA clearance during and after neoadjuvant therapy |
From enrollment to end of treatment at 8 cycles (24 weeks)
|
|
Event-Free Survival (EFS)
Tidsram: From time of enrollment until date of documented progression or date of death from any cause, whichever came first, assessed up to 67 months
|
Time from Enrollment to disease progression precluding surgery, local or distant recurrence, or death from any cause |
From time of enrollment until date of documented progression or date of death from any cause, whichever came first, assessed up to 67 months
|
|
Residual Cancer Burden (RCB)
Tidsram: Time of Surgery, up to 24 weeks post on study
|
Proportion of patients achieving RCB-0 or RCB-1 (minimal residual disease) at surgery based on molecular subtypes |
Time of Surgery, up to 24 weeks post on study
|
|
Adverse Events
Tidsram: From enrollment till Time of Surgery, up to 24 weeks post enrollment
|
From enrollment till Time of Surgery, up to 24 weeks post enrollment
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- IIT2026-13-Bitar-INDEX-HER2
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .